[HBN뉴스 = 정동환 기자] Biobytes announced that it has signed a strategic Memorandum of Understanding (MOU) and a Non-disclosure Agreement (NDA) with Myomar Molecular Inc, the Canadian MDx firm specializing in sarcopenia molecular diagnostics as part of its effort to achieve global expansion.

 

Biabytes, a company specializing in the discovery and development of novel drug biomarkers based on sarcopenia biobank cohort data, has previously collaborated with Hyundai Construction and Engineering through the Seoul Startup Hub Gongdeok Open Innovation Support Program. Through this collaboration, the company gained experience in technology validation and business commercialization with large enterprises, demonstrating both its technological capabilities and market expansion potential simultaneously. Leveraging this experience, the company has solidly built a foundation for strategic partnerships aimed at entering the global market.

Under this agreement, Biobytes will leverage Sarco-Finding, its AI-driven analysis technology for blood and tissue data, to analyze Myomar’s sarcopenia patients’ samples, unveiling the next-generation solution for sarcopenia diagnostic and treatment.

 

 

The partnership is expected to act as a strategic catalyst for scaling Biobytes’s multicenter sarcopenia biobank cohort database Muscle Bank internationally and establishing clinical evidence accepted worldwide.

Lee Jung-woo, the CEO of Biobytes stated, “The partnership will serve as a significant turning point to offer global standards in the sarcopenia sector, transcending a simple technology exchange. We expect to develop new treatments for sarcopenia by leveraging our expertise”

 

Biobytes has been widely recognized for both innovation and commercial viability across various fields, including AI-based diagnostic support medical devices for sarcopenia and functional health supplements designed to improve muscle strength.

Teaming up with medical institutions such as Wonju severance Christian Hospital, Kangbuk Samsung Hospital, and Seoul St. Mary’s Hospital, the company is developing multi-institutional sarcopenia patient biobank cohort database. Based on this resource, it has launched initiatives to transfer technology for 10 novel sarcopenia biomarkers uncovered by the AI-powered platform Sarco-Finding.

[ⓒ HBN뉴스. 무단전재-재배포 금지]